Selective drug delivery approaches to lesioned brain through blood brain barrier disruption

References

• Davson H. Review lecture. The blood-brain barrier. J Physiol. 1976;255:1–28.
   PubMed Web of Science ®Google Scholar
• Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34:207–217.
   PubMed Web of Science ®Google Scholar
• Pincus JB, Kramer B. Comparative study of the concentration of various anions and cations in cerebrospinal fluid and serum. J Biol Chem. 1923;57:463–470.
   Google Scholar
• Kubie LS, Shults GM. Studies on the relationship of the chemical constituents of blood and cerebrospinal fluid. J Exp Med. 1925;11:685–686.
   Google Scholar
• Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discovery. 2016;15:275–292.
   PubMed Web of Science ®Google Scholar
• Liu S, Levine SR, Winn HR. Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies. J Exp Stroke Transl Med. 2011;4:16–23.
   PubMedGoogle Scholar
• Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011;12:169–182.
   PubMed Web of Science ®Google Scholar
• Banks WA. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Des. 2004;10:1365–1370.
   PubMed Web of Science ®Google Scholar
• Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23:682–684.
   PubMed Web of Science ®Google Scholar
• de Gregori S, de Gregori M, Ranzani GN, et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27:1–5.
   PubMed Web of Science ®Google Scholar
• Au-Yeung SC, Rurak DW, Gruber N, et al. A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. Drug Metab Dispos. 2006;34:955–960.
   PubMed Web of Science ®Google Scholar
• Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20:1422–1449.
   PubMed Web of Science ®Google Scholar
• del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35:161–174.
   PubMed Web of Science ®Google Scholar
• Coker GT, Studelska D, Harmon S, et al. Analysis of tyrosine hydroxylase and insulin transcripts in human neuroendocrine tissues. Brain Res Mol Brain Res. 1990;8:93–98.
   PubMedGoogle Scholar
• Skarlatos S, Yoshikawa T, Pardridge WM. Transport of [125I]transferrin through the rat blood-brain barrier. Brain Res. 1995;683:164–171.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem. 2001;76:1597–1600.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001;114:168–172.
   PubMed Web of Science ®Google Scholar
• Vorbrodt AW, Dobrogowska DH, Ueno M, et al. Immunocytochemical studies of protamine-induced blood-brain barrier opening to endogenous albumin. Acta Neuropathol. 1995;89:491–499.
   PubMed Web of Science ®Google Scholar
• Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. Aaps J. 2008;10:455–472.
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Patel HM, Surana SJ, et al. Brain-blood ratio: implications in brain drug delivery. Expert Opin Drug Delivery. 2016;13:85–92.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004;89:807–811.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38:339–348.
   PubMed Web of Science ®Google Scholar
• Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72:648–672.
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543–553.
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37:3300–3317.
   PubMed Web of Science ®Google Scholar
• Kacem K, Lacombe P, Seylaz J, et al. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: a confocal microscopy study. Glia. 1998;23:1–10.
   PubMed Web of Science ®Google Scholar
• Oberoi RK, Parrish KE, Sio TT, et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 2016;18:27–36.
   PubMed Web of Science ®Google Scholar
• Choonara YE, Kumar P, Modi G, et al. Improving drug delivery technology for treating neurodegenerative diseases. Expert Opin Drug Delivery. 2016;13:1029–1043.
   PubMed Web of Science ®Google Scholar
• Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011;10:509–519.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr., Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7:400–408.
   PubMed Web of Science ®Google Scholar
• Burgess A, Hynynen K. Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chem Neurosci. 2013;4:519–526.
   PubMed Web of Science ®Google Scholar
• Burgess KHA. Drug delivery across the blood-brain barrier using focused ultrasound. Expert Opin Drug Delivery. 2014;11:711–721.
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Rossell LA, Kossoff EH, et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res. 2002;48:145–155.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Delivery. 2016;13:963–975.
   PubMed Web of Science ®Google Scholar
• Tayebati SK, Nwankwo IE, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des. 2013;19:510–526.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959–1972.
   PubMed Web of Science ®Google Scholar
• Joshi S, Ergin A, Wang M, et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol. 2011;104:11–19.
   PubMed Web of Science ®Google Scholar
• Hynynen K, McDannold N, Vykhodtseva N, et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640–646.
   PubMed Web of Science ®Google Scholar
• Choi JJ, Wang S, Brown TR, et al. Noninvasive and transient blood-brain barrier opening in the hippocampus of Alzheimer’s double transgenic mice using focused ultrasound. Ultrason Imaging. 2008;30:189–200.
   PubMed Web of Science ®Google Scholar
• Mikitsh JL, Chacko AM. Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspect Medicin Chem. 2014;6:11–24.
   PubMedGoogle Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRX. 2005;2:3–14.
   PubMedGoogle Scholar
• Boado RJ, Hui EK, Lu JZ, et al. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 2010;333:961–969.
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids. 2002;23:65–70.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta, Biomembr. 1975;401:128–136.
   PubMed Web of Science ®Google Scholar
• Su TZ, Lunney E, Campbell G, et al. Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem. 1995;64:2125–2131.
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Davis TP. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv. 2011;2:1015–1041.
   PubMedGoogle Scholar
• Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001;7:115–121.
   PubMed Web of Science ®Google Scholar
• Bielekova B, Kadom N, Fisher E, et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology. 2005;65:1071–1076.
   PubMed Web of Science ®Google Scholar
• Leppert D, Lindberg RL, Kappos L, et al. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev. 2001;36:249–257.
   PubMed Web of Science ®Google Scholar
• Moustafa RR, Baron JC. Clinical review: imaging in ischaemic stroke–implications for acute management. Crit Care. 2007;11:227.
   PubMed Web of Science ®Google Scholar
• Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367–1379.
   PubMed Web of Science ®Google Scholar
• Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232–245.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28:202–208.
   PubMed Web of Science ®Google Scholar
• Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med. 2009;13:2911–2925.
   PubMed Web of Science ®Google Scholar
• Prakash R, Carmichael ST. Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol. 2015;28:556–564.
   PubMed Web of Science ®Google Scholar
• van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain. 2007;130:521–534.
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience. 2003;118:417–429.
   PubMed Web of Science ®Google Scholar
• Shah GN, Price TO, Banks WA, et al. Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis. J Pharmacol Exp Ther. 2013;344:637–645.
   PubMed Web of Science ®Google Scholar
• McCaffrey G, Seelbach MJ, Staatz WD, et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem. 2008;106:2395–2409.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1139–1151.
   PubMed Web of Science ®Google Scholar
• Haley MJ, Lawrence CB.The blood-brain barrier after stroke: structural studies and the role of transcytotic vesicles.J Cereb Blood Flow Metab.2016;28:456-470.
   Google Scholar
• Knowland D, Arac A, Sekiguchi KJ, et al. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron. 2014;82:603–617.
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics. 2003;13:259–263.
   PubMedGoogle Scholar
• Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm. 2008;115:1001–1009.
   PubMed Web of Science ®Google Scholar
• McColl BW, Rothwell NJ, Allan SM. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci. 2008;28:9451–9462.
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood–brain barrier with neurologic outcome after acute stroke. J Nucl Med. 2003;44:1898–1904.
   PubMed Web of Science ®Google Scholar
• Brouns R, Wauters A, de Surgeloose D, et al. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur Neurol. 2011;65:23–31.
   PubMed Web of Science ®Google Scholar
• Kang EJ, Major S, Jorks D, et al. Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions. Neurobiol Dis. 2013;52:204–218.
   PubMed Web of Science ®Google Scholar
• Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540–549.
   PubMed Web of Science ®Google Scholar
• Grossman RI, Gonzalez-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology. 1986;161:721–725.
   PubMed Web of Science ®Google Scholar
• Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480–489.
   PubMed Web of Science ®Google Scholar
• Ortiz GG, Pacheco-Moises FP, Macias-Islas MA, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45:687–697.
   PubMed Web of Science ®Google Scholar
• Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol. 2011;71:1018–1039.
   PubMed Web of Science ®Google Scholar
• Kwon I, Kim EH, del Zoppo GJ, et al. Ultrastructural and temporal changes of the microvascular basement membrane and astrocyte interface following focal cerebral ischemia. J Neurosci Res. 2009;87:668–676.
   PubMed Web of Science ®Google Scholar
• Nishioku T, Dohgu S, Takata F, et al. Detachment of brain pericytes from the basal lamina is involved in disruption of the blood-brain barrier caused by lipopolysaccharide-induced sepsis in mice. Cell Mol Neurobiol. 2009;29:309–316.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–1318.
   PubMed Web of Science ®Google Scholar
• Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083–1099.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Liu M, Ojha T, et al. Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discov Today Technol. 2016;20:41–48.
   PubMedGoogle Scholar
• Cheng Z, Zhang J, Liu H, et al. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer’s disease-related animal models despite reported blood-brain barrier disruption. Drug Metab Dispos. 2010;38:1355–1361.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discovery. 2014;13:813–827.
   PubMed Web of Science ®Google Scholar
• Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomed. 2014;9:4357–4373.
   PubMed Web of Science ®Google Scholar
• Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes. Anticancer Drugs. 2015;26:241–258.
   PubMed Web of Science ®Google Scholar
• Al-Ahmady Z, Kostarelos K. Chemical components for the design of temperature-responsive vesicles as cancer therapeutics. Chem Rev. 2016;116:3883–3918.
   PubMed Web of Science ®Google Scholar
• Al-Ahmady ZS, Chaloin O, Kostarelos K. Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release. 2014;196:332–343.
   PubMed Web of Science ®Google Scholar
• Ozbakir B, Crielaard BJ, Metselaar JM, et al. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release. 2014;190:624–636.
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, Lammers T, Schiffelers RM, et al. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release. 2012;161:225–234.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Delivery Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• Proffitt RT, Satorius A, Chiang SM, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991;28:49–61.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil(R)–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.
   PubMedGoogle Scholar
• Wu NZ, Da D, Rudoll TL, et al. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993;53:3765–3770.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Huang SK, Martin FJ, Jay G, et al. Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 1993;143:10–14.
   PubMed Web of Science ®Google Scholar
• Jiao X, He P, Li Y, et al. The role of circulating tight junction proteins in evaluating blood brain barrier disruption following intracranial hemorrhage. Dis Markers. 2015;860120:25.
   Google Scholar
• Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther Deliv. 2013;4:687–704.
   PubMedGoogle Scholar
• Wei X, Chen X, Ying M, et al. Brain tumor-targeted drug delivery strategies. Acta Pharmaceutica Sinica B. 2014;4:193–201.
   PubMed Web of Science ®Google Scholar
• Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 2005;5:1–2.
   Google Scholar
• Turjeman K, Bavli Y, Kizelsztein P, et al. Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases. PLoS One. 2015;10:e0130442.
   PubMed Web of Science ®Google Scholar
• Fukuta T, Ishii T, Asai T, et al. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. Eur J Pharm Biopharm. 2015;97:1–7.
   PubMed Web of Science ®Google Scholar
• Ishii T, Asai T, Oyama D, et al. Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J Control Release. 2012;160:81–87.
   PubMed Web of Science ®Google Scholar
• Fukuta T, Ishii T, Asai T, et al. Real-time trafficking of PEGylated liposomes in the rodent focal brain ischemia analyzed by positron emission tomography. Artif Organs. 2014;38:662–666.
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Stammes MA, Que I, et al. Effect of PLGA NP size on efficiency to target traumatic brain injury. J Control Release. 2016;223:31–41.
   PubMed Web of Science ®Google Scholar
• Fukuta T, Asai T, Sato A, et al. Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. Int J Pharm. 2016;506:129–137.
   PubMed Web of Science ®Google Scholar
• Kawaguchi AT, Haida M, Ohba H, et al. Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates: longitudinal observation. Artif Organs. 2013;37:904–912.
   PubMedGoogle Scholar
• Kaneda S, Ishizuka T, Sekiguchi A, et al. Efficacy of liposome-encapsulated hemoglobin in a rat model of cerebral ischemia. Artif Organs. 2014;38:650–655.
   PubMed Web of Science ®Google Scholar
• Hamadate N, Yamaguchi T, Sugawara A, et al. Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hippocampal dysfunction after cerebral ischemia in rats. J Pharmacol Sci. 2010;114:409–419.
   PubMed Web of Science ®Google Scholar
• Fukumoto D, Kawaguchi AT, Haida M, et al. Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in rats: effect of oxygen affinity. Artif Organs. 2009;33:159–163.
   PubMed Web of Science ®Google Scholar
• Kawaguchi AT, Fukumoto D, Haida M, et al. Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in the rat: evaluation with photochemically induced thrombosis of the middle cerebral artery. Stroke. 2007;38:1626–1632.
   PubMed Web of Science ®Google Scholar
• Kawaguchi AT, Yamano M, Haida M, et al. Effect of oxygen affinity of liposome-encapsulated hemoglobin on cerebral ischemia and reperfusion as detected by positron emission tomography in nonhuman primates. Artif Organs. 2017;41:336–345.
   PubMed Web of Science ®Google Scholar
• Campos-Martorell M, Cano-Sarabia M, Simats A, et al. Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int J Nanomed. 2016;11:3035–3048.
   PubMed Web of Science ®Google Scholar
• Takanashi Y, Ishida T, Kirchmeier MJ, et al. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. Neurol Med Chir. 2001;41:107–113.
   PubMed Web of Science ®Google Scholar
• Liu H, Jablonska A, Li Y, et al. Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke. Theranostics. 2016;6:1588–1600.
   PubMed Web of Science ®Google Scholar
• Ramos-Cabrer P, Agulla J, Argibay B, et al. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm. 2011;405:228–233.
   PubMed Web of Science ®Google Scholar
• Smith DA, Vaidya SS, Kopechek JA, et al. Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes. Ultrasound Med Biol. 2010;36:145–157.
   PubMed Web of Science ®Google Scholar
• Laing ST, Moody MR, Kim H, et al. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thromb Res. 2012;130:629–635.
   PubMed Web of Science ®Google Scholar
• Kandadai MA, Meunier JM, Hart K, et al. Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis. Transl Stroke Res. 2015;6:78–87.
   PubMed Web of Science ®Google Scholar
• Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol. 2004;188:200–204.
   PubMed Web of Science ®Google Scholar
• Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis. 2004;17(suppl 1):153–166.
   PubMedGoogle Scholar
• Sutherland BA, Minnerup J, Balami JS, et al. Neuroprotection for Ischaemic Stroke: translation from the bench to the bedside. Int J Stroke. 2012;7:407–418.
   PubMed Web of Science ®Google Scholar
• Imaizumi S, Woolworth V, Fishman RA, et al. Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke. 1990;21:1312–1317.
   PubMed Web of Science ®Google Scholar
• Phelan AM, Lange DG. Ischemia/reperfusion-induced changes in membrane fluidity characteristics of brain capillary endothelial cells and its prevention by liposomal-incorporated superoxide dismutase. Biochim Biophys Acta. 1991;5:97–102.
   Google Scholar
• Stanimirovic DB, Markovic M, Micic DV, et al. Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion ‘oxidative stress’ in gerbil brain. Neurochem Res. 1994;19:1473–1478.
   PubMed Web of Science ®Google Scholar
• Yun X, Maximov VD, Yu J, et al. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab. 2013;33:583–592.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Das N, Mandal AK, et al. Mannosylated liposomal cytidine 5ʹ diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. Neurosci. 2010;171:1287–1299.
   PubMed Web of Science ®Google Scholar
• Fresta M, Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline. Life Sci. 1997;61:1227–1235.
   PubMed Web of Science ®Google Scholar
• Fresta M, Puglisi G. Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. Int J Pharm. 1996;134:89–97.
   Web of Science ®Google Scholar
• Fresta M, Wehrli E, Puglisi G. Enhanced therapeutic effect of cytidine-5ʹ-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharm Res. 1995;12:1769–1774.
   PubMed Web of Science ®Google Scholar
• Fresta M, Puglisi G, Di Giacomo C, et al. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J Pharm Pharmacol. 1994;46:974–981.
   PubMed Web of Science ®Google Scholar
• Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. 2002;80:12–23.
   PubMed Web of Science ®Google Scholar
• Secades JJ, Alvarez-Sabin J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016;25:1984–1996.
   PubMed Web of Science ®Google Scholar
• LeVine SM. Albumin and multiple sclerosis. BMC Neurol. 2016;16:016–0564.
   PubMed Web of Science ®Google Scholar
• Spencer JI, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2017;31:2017–316011.
   Google Scholar
• Ishii T, Asai T, Fukuta T, et al. A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion. Int J Pharm. 2012;439:269–274.
   PubMedGoogle Scholar
• Agulla J, Brea D, Campos F, et al. In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics. 2013;4:90–105.
   PubMed Web of Science ®Google Scholar
• Omori N, Maruyama K, Jin G, et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res. 2003;25:275–279.
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Pagel MA, Kroll RA, et al. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery. AJNR Am J Neuroradiol. 1999;20:217–222.
   PubMed Web of Science ®Google Scholar
• Nance E, Timbie K, Miller GW, et al. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. J Control Release. 2014;189:123–132.
   PubMed Web of Science ®Google Scholar
• Åslund AKO, Berg S, Hak S, et al. Nanoparticle delivery to the brain — by focused ultrasound and self-assembled nanoparticle-stabilized microbubbles. J Control Release. 2015;220:287–294.
   PubMed Web of Science ®Google Scholar
• Shen Y, Guo J, Chen G, et al. Delivery of liposomes with different sizes to mice brain after sonication by focused ultrasound in the presence of microbubbles. Ultrasound Med Biol. 2016;42:1499–1511.
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Neuwelt EA. Dose-dependent neurotoxicity (seizures) due to deposition of gadolinium-based contrast agents in the central nervous system. Radiology. 2015 Dec;277(3):925–926.
   PubMed Web of Science ®Google Scholar
• Ose A, Kusuhara H, Endo C, et al. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos. 2010;38:168–176.
   PubMed Web of Science ®Google Scholar
• Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther. 2000;294:73–79.
   PubMed Web of Science ®Google Scholar
• Thompson BJ, Sanchez-Covarrubias L, Slosky LM, et al. Hypoxia/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood-brain barrier: relevance to CNS drug delivery. J Cereb Blood Flow Metab. 2014;34:699–707.
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Finch JD, Demarco KM, et al. Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther. 2011;336:827–839.
   PubMed Web of Science ®Google Scholar
• Doyle KP, Cekanaviciute E, Mamer LE, et al. TGFbeta signaling in the brain increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke. J Neuroinflammation. 2010;7:1742–2094.
   Web of Science ®Google Scholar
• Thompson BJ, Ronaldson PT. Drug delivery to the ischemic brain. Adv Pharmacol. 2014;71:165–202.
   PubMedGoogle Scholar
• State of the nation: stroke statistics. Stroke Association, UK, 2016.
   Google Scholar